subjects will be ineligible for enrollment in the study if they meet any of the following criteria: patient under invasive mechanical ventilation for more than 48 hours allergic or hypersensitive to any of the ingredients. pneumonia caused by bacteria, mycoplasma, chlamydia, legionella, fungi or other viruses. obstructive habp/vabp induced by lung cancer or other known causes. carcinoid syndrome. history of long-term use of immunosuppressive agents. history of class iii or iv pulmonary arterial hypertension. patient with chronic respiratory disease under oxygen therapy. undergoing hemodialysis or peritoneal dialysis. estimated or actual rate of creatinine clearance < 15 ml/min. history of moderate and severe liver disease (child-pugh score >12). history of deep venous thrombosis or pulmonary embolism within the last 3 years. undergoing extracorporeal membrane oxygenation (ecmo) or high-frequency oscillatory ventilation support. patient included in another ongoing interventional therapeutic trial. pregnant or lactating. any condition of unsuitable for the study determined by principal investigator (pi).

subjects will be ineligible for enrollment in the study if they meet any of the following criteria: patient under invasive mechanical ventilation for more than 48 hours allergic or hypersensitive to any of the ingredients. pneumonia caused by bacteria, mycoplasma, chlamydia, legionella, fungi or other viruses. obstructive habp/vabp induced by lung cancer or other known causes. carcinoid syndrome. history of long-term use of immunosuppressive agents. history of class iii or iv pulmonary arterial hypertension. patient with chronic respiratory disease under oxygen therapy. undergoing hemodialysis or peritoneal dialysis. estimated or actual rate of creatinine clearance < 15 ml/min. history of moderate and severe liver disease (child-pugh score >12). history of deep venous thrombosis or pulmonary embolism within the last 3 years. undergoing extracorporeal membrane oxygenation (ecmo) or high-frequency oscillatory ventilation support. patient included in another ongoing interventional therapeutic trial. pregnant or lactating. any condition of unsuitable for the study determined by principal investigator (pi).

None

None

subjects will be ineligible for enrollment in the study if they meet any of the following criteria: patient under invasive mechanical ventilation for more than 48 hours allergic or hypersensitive to any of the ingredients. pneumonia caused by bacteria, mycoplasma, chlamydia, legionella, fungi or other viruses. obstructive habp/vabp induced by lung cancer or other known causes. carcinoid syndrome. history of long-term use of immunosuppressive agents. history of class iii or iv pulmonary arterial hypertension. patient with chronic respiratory disease under oxygen therapy. undergoing hemodialysis or peritoneal dialysis. estimated or actual rate of creatinine clearance < 15 ml/min. history of moderate and severe liver disease (child-pugh score >12). history of deep venous thrombosis or pulmonary embolism within the last 3 years. undergoing extracorporeal membrane oxygenation (ecmo) or high-frequency oscillatory ventilation support. patient included in another ongoing interventional therapeutic trial. pregnant or lactating. any condition of unsuitable for the study determined by principal investigator (pi).

subjects will be ineligible for enrollment in the study if they meet any of the following criteria: patient under invasive mechanical ventilation for more than 48 hours allergic or hypersensitive to any of the ingredients. pneumonia caused by bacteria, mycoplasma, chlamydia, legionella, fungi or other viruses. obstructive habp/vabp induced by lung cancer or other known causes. carcinoid syndrome. history of long-term use of immunosuppressive agents. history of class iii or iv pulmonary arterial hypertension. patient with chronic respiratory disease under oxygen therapy. undergoing hemodialysis or peritoneal dialysis. estimated or actual rate of creatinine clearance < 15 ml/min. history of moderate and severe liver disease (child-pugh score >12). history of deep venous thrombosis or pulmonary embolism within the last 3 years. undergoing extracorporeal membrane oxygenation (ecmo) or high-frequency oscillatory ventilation support. patient included in another ongoing interventional therapeutic trial. pregnant or lactating. any condition of unsuitable for the study determined by principal investigator (pi).